Business Wire

Hoteliers could see 12% increase on room rates by selling their best features or services

20.3.2025 13:00:00 CET | Business Wire | Press Release

Share

New research from technology innovators Amadeus explores what travelers are looking for from a trip and how technology can make those ambitions come true. The report– Travel Dreams – draws on input from 6,000 travelers from US, China, India, UK, France and Germany to understand how they choose where to visit, how they want to book and what factors most impact a trip once they are on the road.

The study finds that two-thirds of hotel guests (63%) are willing to pay extra for features such as a specific view or floor, to have an Xbox in their room or to have local attractions added to their package. The research shows these features could add around 12% to the average daily rate (ADR) charged by the hotel, which could increase revenues by over $5,300 per room*, per year, for an average mid-range hotel chain looking to sell these extra features.

The channels now driving travel are changing too. Social media ads and travel influencers have risen the most in influence in the last five years, while newspapers, in-person travel agents and TV ads are all seeing fluctuations in importance as a source of inspiration for a travelers’ next destination.

Leisure travelers crave the personal touch from hotels, with 50% of travelers saying that receiving a personalized service and welcome would be top of the list in achieving their ideal hotel experience. Over half of guests (52%) said they would be willing to share personal data in return for tailored deals (with fewer people, 40%, open to doing so for a reduced price). Nearly half (48%) of all leisure guests shared a preference for a traditional check-in desk, with a person to talk them through the hotel amenities.

Business travelers are looking for more technology in their pursuit of efficiency, with 71% of business travelers interested in a form of online or self-service check-in. Nearly a quarter (22%) of business travelers want the option of paying with crypto currency or a digital wallet in the future – suggesting the payments landscape may also be shifting.

Lack of insurance is costing travelers real money. The global travelers surveyed said the average amount they think they have lost due to not having travel insurance stands at an average of US$1,210 per person – a sizeable sum. For the average Chinese traveler specifically, they put this figure at over $2,500 per person.

Travelers want to embrace virtual reality and artificial intelligence. 82% of business travelers and 66% of leisure travelers said they would like to explore a destination before arrival with a virtual tour. Half of all travelers said they would now turn to AI to tell them about the best places for dinner at their destination. 18% of travelers said they would even ask an AI assistant to write a review on their behalf about a hotel or dinner they had experienced on their trip.

Commenting on the findings, Francisco Pérez-Lozao Rüter, President, Hospitality, Amadeus, says: “From the moment travelers begin thinking about their trip to the time they return home, our mission is to empower the industry to be able to provide exceptional experiences at every step of the journey.

“Projects of this kind show how diverse people’s needs are, depending on key factors such as the purpose of their trip, their age or where they are from. By combining this knowledge with innovative new technology, hoteliers, destinations, mobility and travel protection providers have real opportunities to drive profitable demand, create personalized trips for guests and connect the dots across the end-to-end experience for people. Working in lock step with our customers, together we are transforming travel.”

Notes to the editors:

Methodology

Findings for Travel Dreams are based on input from 6,000 travelers around the world. Collaborating with Opinium Research, researchers questioned a combination of business and leisure travelers in six key markets – USA, China, Germany, UK, France and India – to deepen understanding of the end-to-end travel experience.

To deliver an industry perspective on the key topics covered in the report, interviews were conducted with executives from Amadeus, Flemings Hotels, Lexis Hotels, The Trans Hotel Group, Marcus Hotels, Geronimo Hospitality Group, Core Hospitality, Hegg Companies, Europcar, ProColombia and AXA Partners.

* To calculate the potential revenue that could be added by selling hotel attributes, the following calculation was used, based on Amadeus Demand360® data:

  • Average hotel occupancy worldwide stood at 69%, or 252 days, in 2024.
  • Average daily rate worldwide in 2024 stood at $178, or $44,856 per annum.
  • Therefore, if travelers are willing to spend an average of 12% on top of ADR for attributes, this could equate to an additional $5,383 per room, per year.

About Amadeus

Amadeus makes the experience of travel better for everyone, everywhere by inspiring innovation, partnerships and responsibility to people, places and planet.

Our technology powers the travel and tourism industry. Inspiring more open ways of working. More connected ways of thinking, centered around the traveler. Our open platform connects the global travel and hospitality ecosystem. From startups to big industry players and governments too. Together, redesigning the travel of tomorrow.

Learn more about Amadeus at www.amadeus.com, and www.amadeus-hospitality.com follow us on:

LinkedIn
Facebook
Instagram
Threads
YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20250320859086/en/

Contacts

Clementine Croton
ccroton@fireoth.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye